International Health Management Association
IHMA supports all phases of anti-infective therapy development, from discovery through commercialization. They are a global antimicrobial partner providing central, reference, and clinical research laboratory services worldwide, with a focus on antimicrobial drug development, surveillance, and clinical trials. IHMA employs state-of-the-art technology and offers customized services to ensure successful drug development, commercialization, and post-marketing pathways.
Industries
Nr. of Employees
medium (51-250)
International Health Management Association
Services
On-site CAP-accredited, CLIA-certified laboratory services for specimen processing, culture, identification, susceptibility testing, and molecular characterization to generate regulatory-ready clinical microbiology data.
Design and execution of multi-region surveillance programs to monitor susceptibility trends and provide long-term datasets for regulatory submissions and medical education.
Access to a continuously expanding, catalogued collection of phenotypically and genotypically characterized isolates and the ability to assemble custom panels by specified criteria.
Custom laboratory studies including bacterial killing, resistance development, drug–drug interaction studies, and quality-control guideline development to support discovery and regulatory filing needs.
Integrated scientific support offering study design consultation, data analysis, preparation of regulatory-ready reports, and authorship support for scientific publications and presentations.
Distribution of research-use-only reagents and materials (drug powders, disks, MIC strips, microdilution panels) to local laboratories to enable early testing of newly launched products prior to commercial diagnostic availability.
On-site CAP-accredited, CLIA-certified laboratory services for specimen processing, culture, identification, susceptibility testing, and molecular characterization to generate regulatory-ready clinical microbiology data.
Design and execution of multi-region surveillance programs to monitor susceptibility trends and provide long-term datasets for regulatory submissions and medical education.
Access to a continuously expanding, catalogued collection of phenotypically and genotypically characterized isolates and the ability to assemble custom panels by specified criteria.
Custom laboratory studies including bacterial killing, resistance development, drug–drug interaction studies, and quality-control guideline development to support discovery and regulatory filing needs.
Integrated scientific support offering study design consultation, data analysis, preparation of regulatory-ready reports, and authorship support for scientific publications and presentations.
Distribution of research-use-only reagents and materials (drug powders, disks, MIC strips, microdilution panels) to local laboratories to enable early testing of newly launched products prior to commercial diagnostic availability.
Expertise Areas
- Antimicrobial resistance surveillance
- Central laboratory microbiology for clinical trials
- Antimicrobial susceptibility testing
- Molecular diagnostics and genotyping
Key Technologies
- Antimicrobial susceptibility testing (broth microdilution, MIC panels, disk diffusion, MIC strips)
- Molecular diagnostics and genotypic characterization
- Culture and organism identification workflows
- Curated isolate biorepository and custom panels
News & Updates
The CAP has awarded renewal of accreditation to IHMA’s Schaumburg, Illinois site following a recent inspection, recognizing IHMA’s high standards in laboratory accreditation.
The CAP has awarded renewal of accreditation to IHMA’s Monthey, Switzerland site, recognizing leadership, innovation, and commitment to excellence in microbiology services.
IHMA supported the TIMM-10 conference, presenting surveillance data on antifungal resistance and participating in scientific discussions.
IHMA participated in the 2023 ASM/ESCMID conference, showcasing their work on antimicrobial resistance and drug development.
IHMA published an article discussing the global challenge of antimicrobial resistance and the importance of surveillance.
IHMA published an article on antifungal resistance monitoring, emphasizing the need for awareness and preparedness.
The CAP has awarded renewal of accreditation to IHMA’s Schaumburg, Illinois site following a recent inspection, recognizing IHMA’s high standards in laboratory accreditation.
The CAP has awarded renewal of accreditation to IHMA’s Monthey, Switzerland site, recognizing leadership, innovation, and commitment to excellence in microbiology services.
IHMA supported the TIMM-10 conference, presenting surveillance data on antifungal resistance and participating in scientific discussions.
IHMA participated in the 2023 ASM/ESCMID conference, showcasing their work on antimicrobial resistance and drug development.
IHMA published an article discussing the global challenge of antimicrobial resistance and the importance of surveillance.
IHMA published an article on antifungal resistance monitoring, emphasizing the need for awareness and preparedness.